Abstract
Objective:
The primary objective of the study is to evaluate, in a population in the state of Bahia, Brazil, the impact of ranibizumab in best-corrected visual acuity of patients with macular disease and macular edema.
Methods:
This study did a retrospective and observational assessment visual acuity of the group of patients followed at the Professor Edgard Santos University Hospital and Oftalmodiagnose Eye Hospital in 2011 and 2012 in a real life context.
Results:
The impact on sample patientes post-treatment demonstrated favorable outcome with an increase in visual acuity of 32%, which means improvement of more than one line in the snellem chart.
Conclusion:
Improvement in visual acuity of this group was observed from baseline to the end of follow up in a real-life context.
Keywords:
Macular degeneration/therapy; Retinal neovascularization; Visual acuity; Monoclonal antibodies/therapeutic use
